Search Results
Your search for ,Per matches 4038 pages
Showing 1651 - 1700Acalabrutinib Improves Progression-Free Survival vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL
As reported in the Journal of Clinical Oncology by Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, Milan, Italy, and colleagues, the phase III ASCEND trial showed significantly prolonged progression-free survival with acalabrutinib monotherapy vs the investigator’s choice of...
Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGFR2 Fusions
At the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 Virtual, Milind Javle, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues reported that third- and later-line treatment with the selective fibroblast growth factor...
Past CMS and FDA Head Discusses Challenges in U.S. Health-Care Policy and Possible Solutions
As evidenced at this year’s ASCO20 Virtual Scientific Program, oncology science, technology, and clinical practice are evolving at a rapid pace, bringing new challenges to the efficient and ethical practice of cancer care at all levels. To shed light on some of the large-scale public health and...
Effect of Mammography Screening From Age 40 on Breast Cancer Mortality: Final Results of the UK Age Trial
As reported in The Lancet Oncology by Duffy et al, final results of the UK Age Trial show that initiation of annual mammography screening for breast cancer at age 40 was associated with a significant reduction in breast cancer mortality at 10 years compared with screening beginning at age 50 years, ...
Current Lung Cancer Screening Guidelines May Underselect Black Ever-Smokers
Public health screening guidelines for lung cancer followed by the U.S. Preventive Services Task Force (USPSTF) and the Centers for Medicare & Medicaid Services (CMS) undercount eligible Black individuals, according to a study by Mary Pasquinelli, DNP, FNP-BC, and colleagues in press at the...
Dabrafenib Plus Trametinib in BRAF V600E–Mutated Tumors: NCI-MATCH Subprotocol H
As reported in the Journal of Clinical Oncology by Salama et al, the NCI-MATCH trial subprotocol H (EAY131-H) has shown durable responses with dabrafenib plus trametinib in previously treated patients with BRAF V600E–mutant tumors. Study Details The study enrolled 35 patients with mixed-histology...
Association of Surgical Volume Pledge With Short-Term Outcomes After Lung Cancer Resection
In a retrospective study reported in the Journal of Clinical Oncology, Farjah et al found that patients who underwent resection for lung cancer at hospitals and with surgeons meeting Volume Pledge criteria did not have better short-term outcomes compared with patients who received care from...
Balancing Efficacy and Safety of Targeted Therapy in Breast Cancer Care
Novel targeted therapies have increased the likelihood of cure and prolonged survival in many patients with advanced breast cancer (Table 1), but these new agents also carry toxicity profiles that vary greatly from those of traditional chemotherapy. During the ASCO20 Virtual Education Program,...
Study Finds Residents of Low-Income Neighborhoods Have Less Access to ICU Beds Amidst Coronavirus Pandemic
A new study published by Kanter et al in Health Affairs sheds light on another reason why the coronavirus pandemic is disproportionately affecting individuals of lower socioeconomic status: residents in low-income neighborhoods lack access to intensive care unit (ICU) beds. While the shortage of...
Nonmetastatic Castration-Resistant Prostate Cancer
Nonmetastatic castration-resistant prostate cancer arises in the subset of men with biochemically recurrent disease (ie, rising prostate-specific antigen [PSA] level after definitive therapy in the absence of metastases) who develop PSA progression after chronic exposure to androgen-deprivation...
Final Overall Survival Analysis of the PROSPER Trial in Nonmetastatic Castration-Resistant Prostate Cancer
In the final overall survival analysis of the phase III PROSPER trial reported at the ASCO20 Virtual Scientific Program1 and published in The New England Journal of Medicine,2 Cora N. Sternberg, MD, and colleagues found that enzalutamide plus androgen-deprivation therapy (ADT) significantly...
Lutetium-177–Labeled PSMA-617 Improves PSA Response in First Analysis From TheraP Trial in Metastatic Prostate Cancer
Initial results of the randomized phase II TheraP trial showed that therapy directed to prostate-specific membrane antigen (PSMA) with lutetium-177–labeled PSMA-617 (LuPSMA) significantly improved prostate-specific antigen (PSA) response compared with cabazitaxel in men with metastatic...
UICC Applauds WHO Global Strategy on Eliminating Cervical Cancer as a Public Health Problem
The Union for International Cancer Control (UICC) lauded the adoption of the World Health Organization’s (WHO) global strategy toward eliminating cervical cancer as a public health problem. WHO Member States adopted the strategy alongside other health resolutions as part of the silence procedure...
10-Year Study Indicates Pembrolizumab Provides Long-Term Benefits for Patients With Metastatic Melanoma
A new 10-year analysis, led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and recently published in JAMA Oncology,1 provides new insights into an important question: whether BRAF V600E/K–mutation status or ...
Pembrolizumab for Cutaneous Squamous Cell Carcinoma
On June 24, 2020, pembrolizumab was approved for treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.1,2 Supporting Efficacy Data Approval was based on findings in the multicenter, multicohort, open-label KEYNOTE-629 trial ...
Pembrolizumab for First-Line Treatment of Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer
On June 29, 2020, pembrolizumab was approved for the first-line treatment of patients with unresectable or metastatic microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) colorectal cancer.1 Supporting Efficacy Data Approval was based on findings in the randomized,...
NRG Oncology Biospecimen Bank Awarded NCI Funding for Next 6 Years
The NRG Oncology Biospecimen Bank will be awarded an additional 6 years of funding from the National Cancer Institute (NCI). This grant will provide biospecimen banking support for the NCI National Clinical Trials Network (NCTN) group NRG Oncology. During the peer-review grant-renewal process, the...
Selinexor in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
On June 22, 2020, the oral nuclear export inhibitor selinexor was granted accelerated approval for treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic...
Highlights of Research in Lymphomas Presented During the EHA25 Virtual Congress
To complement The ASCO Post’s continued coverage of the virtual edition of the 25th European Hematology Association Annual Congress (EHA25 Virtual), here are a few abstracts selected from the meeting proceedings focusing on clinical research in Hodgkin and marginal zone lymphomas. Omission of...
Expert Point of View: David Sallman, MD
David Sallman, MD, an assistant member of the Malignant Hematology Department of Moffitt Cancer Center and Research Institute, Tampa, Florida, commented on the IMerge and QUAZAR studies for The ASCO Post. As background, he noted the “predominant struggle” of patients with lower-risk myelodysplastic ...
Novel Treatments Emerge for Patients With Lower-Risk Myelodysplastic Syndromes
Patients with lower-risk myelodysplastic syndromes (MDS) who are dependent on red blood cell transfusions have limited options, especially if they are no longer responding to erythropoiesis-stimulating agents. Research presented during the virtual edition of the 25th European Hematology Association ...
Can Radiotherapy Be Omitted for Some Patients With PET-Negative, Early-Stage Unfavorable Hodgkin Lymphoma?
The overwhelming majority of patients with early-stage unfavorable Hodgkin lymphoma may no longer require radiotherapy to treat their disease, according to data presented during the virtual edition of the 25th European Hematology Association (EHA) Annual Congress.1 The findings of the randomized,...
Multiple Lesions Not a Contraindication for Cosmetically Acceptable Lumpectomy
More than 70% of women with multiple tumors in a single breast reported good or excellent satisfaction with the cosmetic results of breast-conserving therapy, Alliance (ACOSOG) Z11102 investigators reported at the 2020 American Society of Breast Surgeons (ASBrS) Virtual Scientific Session.1 In...
Refinement of European LeukemiaNet Classification Recommendations for Younger Adults With AML
Findings from a study published by Eisfeld et al in the journal Leukemia could refine an important set of prognostic and treatment recommendations for younger adult patients with acute myeloid leukemia (AML). The retrospective study evaluated the molecular characteristics and outcomes of 863...
Addition of Pegvorhyaluronidase Alfa to Nab-paclitaxel and Gemcitabine in Hyaluronan-High Metastatic Pancreatic Cancer
In the phase III HALO 109-301 trial reported in the Journal of Clinical Oncology, Eric Van Cutsem, MD, PhD, and colleagues found that the addition of pegvorhyaluronidase alfa (PEGPH20) to nab-paclitaxel plus gemcitabine (AG) did not improve overall survival or progression-free survival in patients...
Does Adding Neoadjuvant Chemohormonal Therapy to Surgery in Patients With Localized High-Risk Prostate Cancer Improve Biochemical Progression–Free Survival?
As reported in the Journal of Clinical Oncology by Eastham et al, the phase III CALGB 90203/Alliance trial has shown no improvement in 3-year biochemical progression-free survival (BPFS) with the addition of neoadjuvant chemohormonal therapy to radical prostatectomy in patients with localized...
FDA Approves Atezolizumab Plus Cobimetinib/Vemurafenib for Advanced BRAF V600–Mutated Melanoma
On July 30, the U.S. Food and Drug Administration (FDA) approved the PD-L1 inhibitor atezolizumab (Tecentriq) plus the MEK inhibitor cobimetinib (Cotellic) and the selective BRAF kinase inhibitor vemurafenib (Zelboraf) for the treatment of patients with advanced BRAF V600 mutation–positive...
Addition of Pazopanib to Preoperative Chemoradiotherapy in Children and Adults With Soft-Tissue Sarcoma
In an interim analysis of a joint Children’s Oncology Group and NRG Oncology phase II trial (ARST1321) reported in The Lancet Oncology, Aaron R. Weiss, DO, and colleagues found that the addition of pazopanib to preoperative chemoradiotherapy significantly increased the rate of pathologic...
Outcomes With PET-Directed Therapy for Limited-Stage DLBCL
As reported in the Journal of Clinical Oncology by Daniel O. Persky, MD, and colleagues, the phase II Intergroup National Clinical Trials Network Study S1001 has shown good outcomes with positron-emission tomography (PET)-directed therapy in patients with limited-stage diffuse large B-cell lymphoma ...
FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma
On July 24, the U.S. Food and Drug Administration (FDA) granted accelerated approval to brexucabtagene autoleucel (Tecartus), a CD19-directed genetically modified autologous T-cell immunotherapy, for the treatment of adult patients with relapsed or refractory mantle cell lymphoma. “Tremendous...
If You Have Self-Doubt When Caring for a Loved One With Cancer
When taking care of a loved one with cancer, it’s natural to feel flooded with emotions—grief, guilt, and just plain old exhaustion. Feelings of inadequacy, doubt, or fear can sometimes pop up, too. Maybe you feel like you do not have the necessary skills to be a caregiver; maybe you feel like you...
Two Cohort Studies Identify Risk Factors for Mortality in Patients With Cancer and COVID-19
Two studies recently reported in The Lancet have identified risk factors for mortality among patients with cancer and COVID-19.1,2 As reported by Lennard Y.W. Lee, DPhil, of the Institute of Cancer and Genomic Sciences, University of Birmingham, and colleagues,1 a UK prospective cohort study...
Pembrolizumab for Adult and Pediatric Patients With Tumor Mutational Burden–High Solid Tumors
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On June 16, 2020, pembrolizumab was granted accelerated...
In Case You Missed It: Quick Takes on Novel Therapies for Solid and Hematologic Malignancies
Because of the COVID-19 pandemic, oncology providers from around the world had to forgo their annual trip to McCormick Place—but the show did go on. We all realized important research can still be presented, clinicians and fellow researchers will still listen, and ASCO presentations will still...
Monumental Progress in the Treatment of Diffuse Large B-Cell Lymphoma
Some monuments are difficult to topple. At least that was the case dating back to 1976, when investigators from the Southwest Oncology Group demonstrated the importance of doxorubicin in the treatment of patients with a group of lymphoid malignancies then referred to as diffuse aggressive...
Avapritinib in Advanced PDGFRA D842V–Mutant Gastrointestinal Stromal Tumors
As reported in The Lancet Oncology by Heinrich et al, the phase I NAVIGATOR trial showed that the PDGFRA and KIT kinase inhibitor avapritinib produced a response in patients with PDGFRA D842V–mutant gastrointestinal stromal tumors (GIST). The study supported the January 2020 approval of...
FDA Pipeline: Novel Treatments for Hematologic Malignancies
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Review to pembrolizumab for the second-line treatment of patients with relapsed or refractory Hodgkin lymphoma, and also accepted a supplemental new drug application for selinexor for pretreated patients with multiple myeloma....
VIALE-A Trial Supports Survival Benefit of Venetoclax Plus Azacitidine in Elderly Patients With AML
In the phase III VIALE-A trial, venetoclax added to azacitidine led to a significant and clinically meaningful improvement in response rates and overall survival, as compared with azacitidine alone, in treatment-naive predominantly elderly patients with acute myeloid leukemia (AML) ineligible for...
Outcomes According to BMI in Women Receiving Adjuvant Docetaxel-Based Chemotherapy for Early Breast Cancer
A retrospective analysis from the BIG 2-98 trial reported in the Journal of Clinical Oncology by Desmedt et al showed poorer disease-free and overall survival with increasing baseline body mass index (BMI) in women receiving adjuvant docetaxel-based chemotherapy but not among those receiving...
Do Not Rush to High-Dose Twice-Daily Radiation for Limited Small Cell Lung Cancer
Bjørn Henning Gronberg, MD, PhD, presented a paper at the ASCO20 Virtual Scientific Program reporting astounding positive results favoring higher-dose, twice-daily radiation therapy in limited-stage small cell lung cancer.1 This was a phase II study (large for phase II but small for phase III)...
The 21st Century Cures Act: A Look Back, a Look Ahead
It was ambitious and it was controversial, but the bipartisan 21st Century Cures Act (Cures) made it through both houses of Congress and was signed into law in December 2016. Sponsored by Representatives Diana DeGette (D-CO) and Fred Upton (R-MI), the landmark legislation funded new medical...
A Long-Time Student of Leadership, Brian J. Bolwell, MD, FACP, Ultimately Takes the Reins at the Taussig Cancer Institute
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, interviewed his colleague Brian J. Bolwell, MD, FACP, Chairman of the Cleveland Clinic Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic. Among other things, Dr. Bolwell discussed his...
Nivolumab Plus Ipilimumab in Two New Lung Cancer Indications
The combination of nivolumab and ipilimumab was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with non–small cell lung cancer (NSCLC) in two different regimens: On May 15, 2020, the two-drug combination was approved for first-line treatment in...
Early Screening With MRI May Reduce Breast Cancer Mortality in Survivors of Childhood Cancer Treated With Chest Radiation
The early initiation—at age 25 to 30—of annual breast cancer screening with magnetic resonance imaging (MRI) with or without mammography may reduce breast cancer mortality by more than half in survivors of childhood cancer who had been previously exposed to chest radiation, according to a study by...
USPSTF Issues Draft Recommendation Statement on Screening for Lung Cancer
On July 7, the U.S. Preventive Services Task Force (USPSTF) posted a draft recommendation statement, draft evidence review, and draft modeling study on screening for lung cancer in people who do not have signs or symptoms. Based on the evidence, the USPSTF recommends annual screening using a...
ESMO World GI: Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGFR2 Fusions
At the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 Virtual, Javle et al reported that third- and later-line treatment with the selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor infigratinib resulted in a progression-free survival and...
Expert Point of View: Jesús G. Berdeja, MD
The importance of first-line therapy in multiple myeloma is that the first therapy typically achieves the most impact, and subsequent lines of therapy tend to be less effective, explained ENDURANCE study discussant Jesús G. Berdeja, MD, Director of Myeloma Research at the Sarah Cannon Research...
Patient Factors Associated With Lack of Provider Recommendation for HPV Vaccination in Young Cancer Survivors
In a study reported in the Journal of Clinical Oncology, York et al found that perceived lack of insurance coverage for human papillomavirus (HPV) vaccine, male sex, and decreased parent-survivor communication regarding HPV vaccination were among the factors associated with an increased likelihood...
Third- or Later-Line Treatment With Infigratinib in Patients With Cholangiocarcinoma and FGR2 Fusions
At the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2020 Virtual, Javle et al reported that third- and later-line treatment with the selective fibroblast growth factor receptor (FGFR) 1–3 inhibitor infigratinib resulted in a progression-free survival and...
Extended-Fraction Radiation Therapy for Bone Metastases Represents Low-Value Care but Continues to Be Widely Practiced
An analysis of radiation therapy patterns among more than 12,000 Medicare patients treated for bone metastases found that 23.4% received extended-fraction radiation therapy, “wasting both health-care dollars and precious patient time,” according to the investigators.1 One-third of the treating...
